Medication info
Olmedica HCT Tablet 5/40/12.5 mg

Olmedica HCT Tablet 5/40/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets (10 tablets/Alu-Alu × 3)
Approval status
Active

MFDS item code 201903061 · Approved 2019.05.10 · Insurance code 649605030

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. It is recommended to take it at the same time each day (e.g., in the morning), if possible. Before administering this drug, it is recommended that the dose of the individual ingredients (olmesartan medoxomil and amlodipine as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this drug may be considered as follows. The maximum dose of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this drug 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this drug 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/25mg or this drug 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The content of each ingredient is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this drug for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. Do not administer this drug to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use caution when administering to patients with mild to moderate hepatic impairment. The maximum dose of this drug for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. Do not administer this drug to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Use very close monitoring when administering this drug, particularly in patients 75 years and older, because experience with its use in this age group is very limited.
Child dose
Administration of this drug is not recommended in pediatric patients under 18 years because safety and efficacy have not been established.

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy

  • Essential hypertension
View approved original text

The combination therapy of Amlodipine and Olmesartan Medoxomil is used when blood pressure is not adequately controlled in patients with essential hypertension. This medication helps effectively manage blood pressure by dilating blood vessels and lowering vascular pressure. As a combination drug, the two medications work complementarily to enhance blood pressure control effects. Therefore, it is useful in the treatment of patients with difficult-to-control blood pressure.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. It is recommended to take it at the same time each day (e.g., in the morning), if possible. Before administering this drug, it is recommended that the dose of the individual ingredients (olmesartan medoxomil and amlodipine as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this drug may be considered as follows. The maximum dose of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this drug 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this drug 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this drug 5/40/25mg or this drug 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The content of each ingredient is listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this drug for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. Do not administer this drug to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use caution when administering to patients with mild to moderate hepatic impairment. The maximum dose of this drug for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. Do not administer this drug to patients with severe hepatic impairment. Elderly patients (65 years and older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Use very close monitoring when administering this drug, particularly in patients 75 years and older, because experience with its use in this age group is very limited.

Child dose

Administration of this drug is not recommended in pediatric patients under 18 years because safety and efficacy have not been established.

Precautions

This medication may cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies or hypersensitivity to this medication, its components, or related class drugs should not take it. Patients with severe hypotension, serious heart disease, unstable heart failure after acute myocardial infarction, or severe renal or hepatic diseases should not use this medication as well. Patients with reduced blood volume or electrolytes may experience hypotension when starting this medication, so their condition should be closely monitored, and in case of hypotension, they should lie down and receive treatment immediately. This medication has a strong blood pressure-lowering effect, so caution is required when used with other antihypertensives, especially with lithium, certain pain relievers, diuretics, etc., as the risk of side effects may increase. While taking this medication, electrolyte levels in the blood and renal function should be regularly monitored, and care should be taken to ensure potassium levels do not become too high or too low. This medication may cause symptoms such as dizziness or drowsiness; therefore, caution is needed when driving or operating dangerous machinery. Rarely, side effects such as skin rash, itching, severe allergic reactions, liver function abnormalities, and blood abnormalities may occur, so patients should consult a doctor immediately if they experience abnormal symptoms. Pregnant or breastfeeding women are advised not to use this medication, especially during pregnancy, as it may pose risks to the fetus, and should avoid taking it. Elderly patients may have impaired renal or hepatic function; therefore, they should start at a lower dosage, and their condition should be monitored closely. In case of overdose, severe hypotension, palpitations, bradycardia, and other symptoms may occur, so appropriate medical treatment should be sought immediately.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion state, depression, apathy, hypersensitivity, anxiety, mood changes, sleep disturbances, orthostatic dizziness, syncope, taste disorders, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, reduced tears, worsening myopia, jaundice, dizziness, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habit, abdominal distension, dyspepsia, gastritis, stomach discomfort, gastroenteritis, gingival hyperplasia, paralytic obstruction, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, vascular edema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, desquamative dermatitis, hyperhidrosis, photochemical reaction, pruritus, purpura, Quincke's edema, rash, recurrence of lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased urinary frequency, acute renal failure, hematuria, dysuria, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial edema, increased blood creatinine, elevated blood urea, increased blood uric acid, decreased blood potassium, increased gamma-glutamyl transpeptidase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, increased blood creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, intestinal vascular edema, altered consciousness, drug hypersensitivity, epigastric pain, decreased libido, hyposmia, asthenia, loss of consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal distention, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is best stored at room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets (10 tablets/Alu-Alu × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.